Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition, Collaboration Agreements and Other (Details Narrative)

v3.24.2.u1
Revenue Recognition, Collaboration Agreements and Other (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Apr. 08, 2022
Dec. 12, 2019
Jun. 30, 2024
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenue       $ 1,096
BioNTech Agreement [Member]              
Fees received $ 2,750            
Deferred revenue $ 2,750            
Revenue recognized         $ 688    
Revenue         $ 375    
Genentech Feasibility Study Agreement [Member]              
Revenue   $ 33          
Genentech Feasibility Study Agreement [Member] | Three Molecules [Member]              
Revenue recognized   $ 100          
Genentech Feasibility Study Agreement [Member] | Genentech [Member]              
Agreement description   Genentech paid the Company a total of $100 for the development of three molecules, or $33 per molecule, which is being recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement.